Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection

Emerging Infectious Diseases

Volumn 10, Issue 1, 2004, Pages 109-116

  Murphy, Edward L ^a   Wang, Baoguang ^b   Sacher, Ronald A ^c   Fridey, Joy ^d   Smith, James W ^e   Nass, Catharie C ^f   Newman, Bruce ^f   Ownby, Helen E ^f   Garratty, George ^f   Hutching, Sheila T ^f   Schreiber, George B ^b  

^a Blood Centers of the Pacific   (United States)

^b WESTAT   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d Blood Bank of San Bernardino and Riverside Counties   (United States)

^e Oklahoma Blood Institute   (United States)

^f AMERICAN RED CROSS BLOOD SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTHRITIS; ARTICLE; ASTHMA; BLADDER; BRONCHITIS; CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HYPERTENSION; IMMUNE RESPONSE; INCIDENCE; KIDNEY INFECTION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 9144259238     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1001.020714     Document Type: Article

References (38)

1. Slattery JP, Franchini G, Gessain A. Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses. Genome Res 1999;9:525-40.
2. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999;353:1951-8.
3. Gebretsadik T, Murphy EL. Counseling and medical evaluation of HTLV-I- and HTLV-II-infected patients. AIDS Clin Rev 1993-94:19-41.
4. Hall WW, Ishak R, Zhu SW, Novoa P, Eiraku N, Takahashi H, et al. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1):S204-14.
5. Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K, et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II infected blood donors. Neurology 1997;48:315-20.
6. Marutsuka K, Suzumiya J, Sumiyoshi A. Cavitating Pneumocystis pneumonia in an autopsied case of adult T-cell leukemia. Int J Hematol 1992;56:233-7.
7. Robinson RD, Lindo JF, Neva FA, Gam AA, Vogel P, Terry SI, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994;169:692-6.
8. Watanabe T, Mochizuki M, Yamaguchi K. HTLV-I uveitis (HU). Leukemia 1997;11(Suppl 3):582-4.
9. Sugimoto M, Nakashima H, Watanabe S, Uyama E, Tanaka F, Ando M, et al. T-lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 1987;2:1220.
10. Mita S, Sugimoto M, Nakamura M, Murakami T, Tokunaga M, Uyama E, et al. Increased human T lymphotropic virus type-I (HTLV-I) proviral DNA in peripheral blood mononuclear cells and bronchoalveolar lavage cells from Japanese patients with HTLV-I-associated myelopathy. Am J Trop Med Hyg 1993;48:170-7.
11. Nishioka K. HTLV-I arthropathy and Sjogren syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(Suppl 1):S57-62.
12. McCallum RM, Patel DD, Moore JO, Haynes BF. Arthritis syndromes associated with human T cell lymphotropic virus type I infection. Med Clin North Am 1997;81:261-76.
13. Stuver SO, Tachibana N, Okayama A, Mueller NE. Evaluation of morbidity among human T lymphotropic virus type I carriers in Miyazaki, Japan. J Infect Dis 1996;173:584-91.
14. Stuver SO, Okayama A, Tachibana N, Tsubouchi H, Mueller NE, Tabor E. HCV infection and liver cancer mortality in a Japanese population with HTLV-I. Int J Cancer. 1996;67:35-7.
15. Modahl LA, Young K, Varney K, Khayam-Bashi H, Murphy EL. Are HTLV-II-seropositive injection drug users at increased risk for bacterial pneumonia, abscess and lymphadenopathy? J Acq Immun Defic Syndr Hum Retrovirol 1997;16:169-75.
16. Murphy EL, Glynn S, Fridey J, Sacher RA, Smith J, Wright DJ, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis 1997;176:1468-75.
17. Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC, et al. Increased incidence of infectious diseases and neurologic abnormalities during prospective follow-up of HTLV-II and -I infected blood donors. Arch Intern Med 1999;159:1485-91.
18. Busch MP, Laycock M, Kleinman SH, Wages JW Jr, Calabro M, Kaplan JE, et al. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study. Blood 1994;83:1143-8.
19. SAS Institute, Inc., SAS/STAT(r) user's guide, version 8, Cary, NC: SAS Institute Inc.; 1999.
20. Robert-Guroff M, Weiss SH, Giron JA, Jennings AM, Ginzburg HM, Margolis IB, et al. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA 1986;255:3133-7.
21. Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis 2001;33:35-40.
22. LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W. Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990;336:1345-7.
23. Safaeian M, Wilson LE, Taylor E, Thomas DL, Vlahov D. HTLV-II and bacterial infections among injection drug users. J Acquir Immune Defic Syndr 2000;24:483-7.
24. Marsh BJ. Infectious complications of human T cell leukemia/lymphoma virus type I infection. Clin Infect Dis 1996;23:138-45.
25. Lal RB, Owen SM, Rudolph DL, Dawson C, Prince H. In vivo cellular tropism of human T-lymphotropic virus type II is not restricted to CD8+ cells. Virology 1995;210:441-7.
26. Murphy EL, Wu Y, Ownby HE, Smith JW, Ruedy RK, Thomson RA, et al. Delayed hypersensitivity skin testing to mumps and Candida albicans antigens is normal in middle-aged HTLV-I- and-II-infected U.S. cohorts. AIDS Res Hum Retroviruses 2001;17:1273-7.
27. Prince HE, Jensen ER, York J. Lymphocyte subsets in HTLV-II-infected former blood donors: relationship to spontaneous lymphocyte proliferation. Clin Immunol Immunopathol 1992;65:201-6.
28. Klimas NG, Page JB, Patarca R, Chitwood D, Morgan R, Fletcher MA. Effects of retroviral infections on immune function in African-American intravenous drug users. AIDS 1993;7:331-5.
29. Rosenblatt JD, Plaeger-Marshall S, Giorgi JV, Swanson P, Chen IS, Chin E, et al. A clinical, hematologic, and immunologic analysis of 21 HTLV-II-infected intravenous drug users. Blood 1990;76:409-17.
30. Bovolenta C, Pilotti E, Mauri M, Turci M, Ciancianaini P, Fisicaro P, et al. Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STATI and STAT5 by secretion of interferon-gamma and granulocyte macrophage-colony-stimulating factor. Blood 2002;99:224-31.
31. Lewis MJ, Gautier VW, Wang XP, Kaplan MH, Hall WW. Spontaneous production of C-C chemokines by individuals infected with human T lymphotropic virus type II (HTLV-II) alone and HTLV-II/HIV-I coinfected individuals. J Immunol 2000;165:4127-32.
32. Zehender G, Meroni L, Varchetta S, De Maddalena C, Cavalli B, Gianotto M, Bet al. Human T-lymphotropic virus type 2 (HTLV-2) provir us in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type I and HTLV-2 and having predominantly sensory polyneuropathy. J Virol 1998;72:7664-8.
33. Stuver SO, Tachibana N, Okayama A, Mueller NE. Evaluation of morbidity among human T lymphotropic virus type 1 carriers in Miyazaki, Japan. J Infect Dis 1996;173:584-91.
34. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, et al. Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet 1985;2:407-10.
35. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031-2.36.
36. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001;183(Suppl 1):S1-4.
37. Stuver SO, Okayama A, Tachibana N, Tsubouchi H, Mueller NE, Tabor E. HCV infection and liver cancer mortality in a Japanese population with HTLV-I. Int J Cancer 1996;67:35-7.
38. Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type 1 in Miyazaki, Japan. J Infect Dis 2000;181:35-41.